ES2679374T3 - Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas - Google Patents

Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas Download PDF

Info

Publication number
ES2679374T3
ES2679374T3 ES13802834.5T ES13802834T ES2679374T3 ES 2679374 T3 ES2679374 T3 ES 2679374T3 ES 13802834 T ES13802834 T ES 13802834T ES 2679374 T3 ES2679374 T3 ES 2679374T3
Authority
ES
Spain
Prior art keywords
seq
igf
amino acid
ggggs
gap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13802834.5T
Other languages
English (en)
Spanish (es)
Inventor
Mika Aoyagi-Scharber
Teresa Margaret Christianson
Melita Dvorak-Ewell
Daniel J. Wendt
Shinong Long
Jonathan Lebowitz
Daniel Solomon GOLD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Application granted granted Critical
Publication of ES2679374T3 publication Critical patent/ES2679374T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105Alpha-N-acetylglucosaminidase (3.2.1.50)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES13802834.5T 2012-11-27 2013-11-27 Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas Active ES2679374T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261730378P 2012-11-27 2012-11-27
US201261730378P 2012-11-27
US201361788968P 2013-03-15 2013-03-15
US201361788968P 2013-03-15
PCT/US2013/072287 WO2014085621A1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
ES2679374T3 true ES2679374T3 (es) 2018-08-24

Family

ID=49753532

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13802834.5T Active ES2679374T3 (es) 2012-11-27 2013-11-27 Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
ES16182420T Active ES2729997T3 (es) 2012-11-27 2013-11-27 Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16182420T Active ES2729997T3 (es) 2012-11-27 2013-11-27 Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas

Country Status (26)

Country Link
US (9) US9376480B2 (enExample)
EP (2) EP2925776B1 (enExample)
JP (2) JP6831176B2 (enExample)
KR (4) KR20230054482A (enExample)
CN (1) CN104822701B (enExample)
AR (1) AR093626A1 (enExample)
AU (1) AU2013352184B2 (enExample)
BR (1) BR112015012152B1 (enExample)
CA (1) CA2892146A1 (enExample)
CL (1) CL2015001371A1 (enExample)
CY (1) CY1122555T1 (enExample)
DK (2) DK2925776T3 (enExample)
ES (2) ES2679374T3 (enExample)
HR (2) HRP20181351T1 (enExample)
HU (2) HUE039334T2 (enExample)
IL (3) IL238824B (enExample)
LT (1) LT3115372T (enExample)
MX (2) MX377150B (enExample)
PL (2) PL2925776T3 (enExample)
PT (2) PT3115372T (enExample)
RS (1) RS58916B1 (enExample)
RU (1) RU2680581C2 (enExample)
SI (1) SI3115372T1 (enExample)
TW (2) TWI711632B (enExample)
WO (1) WO2014085621A1 (enExample)
ZA (1) ZA201503509B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066422B (zh) 2008-05-07 2015-07-22 宝玛瑞制药公司 溶酶体靶向肽及其应用
MX377150B (es) 2012-11-27 2025-03-07 Biomarin Pharm Inc Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
KR20240093939A (ko) 2013-05-15 2024-06-24 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
EP3185889B1 (en) * 2014-08-11 2020-07-15 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
US20180303877A1 (en) * 2014-09-25 2018-10-25 The General Hospital Corporation Cell-based targeted delivery of pseudonomas exotoxin
WO2016065319A1 (en) * 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
US11191844B2 (en) 2015-07-06 2021-12-07 Regeneran Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
EP3371593B1 (en) 2015-11-06 2020-10-14 BioMarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
JP7109369B2 (ja) 2016-02-24 2022-07-29 バイオマリン ファーマシューティカル インコーポレイテッド ターゲティングされた治療用リソソーム酵素融合タンパク質、関連する製剤、およびその使用
SG10201912761UA (en) 2016-04-15 2020-02-27 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
IL271193B2 (en) 2017-06-07 2025-01-01 Regeneron Pharma Preparations and methods for internalizing enzymes
KR20250161673A (ko) 2017-09-22 2025-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 酵素補充療法用酵素を含む融合タンパク質
WO2019157224A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
AU2019231889A1 (en) * 2018-03-09 2020-10-01 Avrobio, Inc. Compositions and methods for treating Parkinson's disease
EP3788064A1 (en) * 2018-04-30 2021-03-10 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
AU2019269685B2 (en) 2018-05-17 2025-12-04 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
CN112243444A (zh) 2018-06-08 2021-01-19 豪夫迈·罗氏有限公司 具有减少的翻译后修饰的肽接头
JP7577650B2 (ja) 2018-10-10 2024-11-05 アミカス セラピューティックス インコーポレイテッド ジスルフィド結合により安定したポリペプチド組成物及びその使用方法
WO2020102667A2 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
CA3154189A1 (en) * 2019-10-10 2021-04-15 Hung Do Variant igf2 constructs
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
WO2022271981A2 (en) 2021-06-23 2022-12-29 Lycia Therapeutics, Inc. Bifunctional compounds containing igf-2 polypeptides
CN115975039A (zh) * 2021-10-15 2023-04-18 中山大学 重组融合抗体和抗体-药物偶联物及其用途
IL321908A (en) * 2023-01-27 2025-09-01 Regeneron Pharma Different rhabdomyovirus glycoproteins and their use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de) 2000-07-20 2002-07-18 Tuma Wolfgang Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
WO2003102583A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
JP4641705B2 (ja) 2001-04-30 2011-03-02 ザイストール セラピューティクス, インコーポレイテッド 治療的タンパク質の亜細胞標的化
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2463473A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Targeted therapeutic proteins
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
ES2344302T3 (es) * 2004-02-10 2010-08-24 Zystor Therapeutics , Inc. Alfa glucosidasa acida y fragmentos de la misma.
US7678371B2 (en) 2005-03-04 2010-03-16 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
CN102066422B (zh) * 2008-05-07 2015-07-22 宝玛瑞制药公司 溶酶体靶向肽及其应用
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
WO2010148253A2 (en) * 2009-06-17 2010-12-23 Zystor Therapeutics, Inc. Formulations for lysosomal enzymes
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群b型の処置
CA2803302C (en) 2010-06-25 2018-03-06 Amcor Limited Oxygen scavenging system for a container
US9409950B2 (en) * 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
CN106279433A (zh) * 2011-03-04 2017-01-04 夏尔人类遗传治疗公司 用于多肽组成物的肽连接物及其使用方法
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2012122477A1 (en) * 2011-03-10 2012-09-13 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
MX377150B (es) 2012-11-27 2025-03-07 Biomarin Pharm Inc Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.

Also Published As

Publication number Publication date
DK3115372T3 (da) 2019-06-11
HUE043679T2 (hu) 2019-09-30
US20190225666A1 (en) 2019-07-25
US11254725B2 (en) 2022-02-22
KR102385392B1 (ko) 2022-04-11
AU2013352184A1 (en) 2015-06-04
MX2019009191A (es) 2019-10-09
LT3115372T (lt) 2019-06-25
CL2015001371A1 (es) 2015-10-09
HRP20190918T1 (hr) 2019-09-20
RS58916B1 (sr) 2019-08-30
US20140161788A1 (en) 2014-06-12
US9834587B2 (en) 2017-12-05
US20250388644A1 (en) 2025-12-25
EP3115372B1 (en) 2019-03-06
HRP20181351T1 (hr) 2018-11-02
SI3115372T1 (sl) 2019-08-30
KR20210070389A (ko) 2021-06-14
RU2015125491A (ru) 2017-01-10
AR093626A1 (es) 2015-06-17
MX2015006644A (es) 2015-08-10
IL238824B (en) 2018-11-29
EP2925776B1 (en) 2018-05-30
CN104822701B (zh) 2018-09-21
PT2925776T (pt) 2018-07-30
US20160039900A1 (en) 2016-02-11
JP2019206556A (ja) 2019-12-05
KR20220047892A (ko) 2022-04-19
US9834588B2 (en) 2017-12-05
KR20150088317A (ko) 2015-07-31
PL3115372T3 (pl) 2019-09-30
PT3115372T (pt) 2019-06-12
ZA201503509B (en) 2016-11-30
US9376480B2 (en) 2016-06-28
EP2925776A1 (en) 2015-10-07
MX367024B (es) 2019-08-02
IL272854A (en) 2020-04-30
US20160031965A1 (en) 2016-02-04
KR20230054482A (ko) 2023-04-24
TW201827468A (zh) 2018-08-01
CN104822701A (zh) 2015-08-05
AU2013352184B2 (en) 2018-05-31
JP2016505539A (ja) 2016-02-25
TW201431884A (zh) 2014-08-16
IL272854B (en) 2021-07-29
ES2729997T3 (es) 2019-11-07
TWI626250B (zh) 2018-06-11
BR112015012152A2 (pt) 2017-08-15
JP6913719B2 (ja) 2021-08-04
IL262976A (en) 2018-12-31
IL238824A0 (en) 2015-06-30
EP3115372A1 (en) 2017-01-11
DK2925776T3 (en) 2018-09-03
US20220127326A1 (en) 2022-04-28
US20170355744A1 (en) 2017-12-14
HUE039334T2 (hu) 2018-12-28
IL262976B (en) 2020-02-27
RU2680581C2 (ru) 2019-02-22
JP6831176B2 (ja) 2021-02-17
PL2925776T3 (pl) 2018-11-30
US10301369B2 (en) 2019-05-28
WO2014085621A1 (en) 2014-06-05
MX377150B (es) 2025-03-07
BR112015012152B1 (pt) 2023-04-25
US20160031964A1 (en) 2016-02-04
HK1216026A1 (en) 2016-10-07
US9845346B2 (en) 2017-12-19
US9771408B2 (en) 2017-09-26
TWI711632B (zh) 2020-12-01
CY1122555T1 (el) 2021-01-27
US20160031963A1 (en) 2016-02-04
KR102262882B1 (ko) 2021-06-10
CA2892146A1 (en) 2014-06-05
KR102521039B1 (ko) 2023-04-12

Similar Documents

Publication Publication Date Title
ES2679374T3 (es) Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
ES2629853T3 (es) Péptidos de dirección lisosómica y usos de los mismos
HK1232896A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1216026B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1250042B (en) Lysosomal targeting peptides and uses thereof
HK1153204A (en) Lysosomal targeting peptides and uses thereof
HK1153204B (en) Lysosomal targeting peptides and uses thereof